2026 Q3 - tulosraportti
7 päivää sitten
‧32 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 105 | ||
| 3 328 | ||
| 470 | ||
| 341 | ||
| 81 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·1 päivä sittenIt will be interesting to see if I manage to lose 50.000 this year, the opportunities are there.
Looking at the history of the board here, the same names keep appearing in several of the same companies. May seem like a network of familiar people. They also have no product success in any of their companies. Historically many share issues/reverse splits. These are people who know how to make money off the shareholders.
·1 päivä sittenWith a reverse split of 1:1000, the price at the current price will be 10kr. So if you previously had 625,000 shares at 0.01, after the split you will have 625 shares at 10 kr. The value will thus be the same. After this, there will definitely be a rights issue, where the issue price might be 5-7kr. What will then happen is that the price will plummet from 10kr to the issue price of maybe 5 or 7, or whatever the issue price turns out to be. So I think everyone can probably figure out that it is not very wise to buy shares in this one, or to hold them when the rights issue is announced....
Hopefully Alligator will also bring in some money via TO15 and TO16.
·1 päivä sittenExciting to see how long Alligator can keep the death spiral going. There will probably be a new capital raise soon, where the guarantors get a hefty discount, so all ordinary shareholders can once again bear the brunt of a new massive dilution. Unfortunately, this method is quite popular for many small biotech companies (and often the only opportunity to get some cash in the box), but too little money is always raised to make a real difference for the company. The only ones who win from these small emissions are the guarantors, who exploit this trick to make money off naive small investors.The latest new share issue was subscribed to 17,1%. I don't think Alligator will bring in any more money via new share issues. Possibly Alligator will bring in some money via TO15 and TO16….
·23.10.So I have bought 625,000 for the risk portfolio - which is very small and plays with binary events. It can then sit until 2027-2028 and see if anything happens there.
there is probably a risk of an emi going forward yes absolutely, unless they come up with something shortly
·22.10.Søren Bregenholt thanks for our patience :) During his time, the share has ONLY fallen by 99.999 % if we go back from when they started, the share has fallen by 99.9999 % meaning one 9 digit extra. It has been a joke to be an investor at Alligator Bioscience AB, they have made maximal dilution every single time but the funny thing is if they get through and succeed with HLX22 and Henlius gets it marketed and starts selling the medicine then Alligator Bioscience AB can have the potential to rise 10-100 times in a very short time. We will see if they go bankrupt or they are going up by 10-100 times. If they get their Mitazalimab project sold, it could potentially also rise many times, but as Søren just said, it is an agreement that will probably be made based on very little money upfront. I am staying in the share and then it must make or break and if it goes bankrupt then I at least have many years where I do not have to pay tax on share gains and that is positive or... :) It is not going to go bankrupt for the next half year or so because now they have money well into mid-late 2027 Søren Bregenholt and the management of Alligator Bioscience AB should have allied with Saniona and Sprint Bioscience then they might have learned something about how to get lucrative deals closed in the biotech market without continuing to dilute shareholders. Just in the current year, it has fallen by 96.85 % .......... Good day out there and good wind Disclaimer: I own shares in Alligator Bioscience and this is not a recommendation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI may also be wrong in what it has found.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 350 801 | 8 350 801 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 350 801 | 8 350 801 | 0 | 0 |
2026 Q3 - tulosraportti
7 päivää sitten
‧32 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenIt will be interesting to see if I manage to lose 50.000 this year, the opportunities are there.Looking at the history of the board here, the same names keep appearing in several of the same companies. May seem like a network of familiar people. They also have no product success in any of their companies. Historically many share issues/reverse splits. These are people who know how to make money off the shareholders.
- ·1 päivä sittenWith a reverse split of 1:1000, the price at the current price will be 10kr. So if you previously had 625,000 shares at 0.01, after the split you will have 625 shares at 10 kr. The value will thus be the same. After this, there will definitely be a rights issue, where the issue price might be 5-7kr. What will then happen is that the price will plummet from 10kr to the issue price of maybe 5 or 7, or whatever the issue price turns out to be. So I think everyone can probably figure out that it is not very wise to buy shares in this one, or to hold them when the rights issue is announced....Hopefully Alligator will also bring in some money via TO15 and TO16.
- ·1 päivä sittenExciting to see how long Alligator can keep the death spiral going. There will probably be a new capital raise soon, where the guarantors get a hefty discount, so all ordinary shareholders can once again bear the brunt of a new massive dilution. Unfortunately, this method is quite popular for many small biotech companies (and often the only opportunity to get some cash in the box), but too little money is always raised to make a real difference for the company. The only ones who win from these small emissions are the guarantors, who exploit this trick to make money off naive small investors.The latest new share issue was subscribed to 17,1%. I don't think Alligator will bring in any more money via new share issues. Possibly Alligator will bring in some money via TO15 and TO16….
- ·23.10.So I have bought 625,000 for the risk portfolio - which is very small and plays with binary events. It can then sit until 2027-2028 and see if anything happens there.there is probably a risk of an emi going forward yes absolutely, unless they come up with something shortly
- ·22.10.Søren Bregenholt thanks for our patience :) During his time, the share has ONLY fallen by 99.999 % if we go back from when they started, the share has fallen by 99.9999 % meaning one 9 digit extra. It has been a joke to be an investor at Alligator Bioscience AB, they have made maximal dilution every single time but the funny thing is if they get through and succeed with HLX22 and Henlius gets it marketed and starts selling the medicine then Alligator Bioscience AB can have the potential to rise 10-100 times in a very short time. We will see if they go bankrupt or they are going up by 10-100 times. If they get their Mitazalimab project sold, it could potentially also rise many times, but as Søren just said, it is an agreement that will probably be made based on very little money upfront. I am staying in the share and then it must make or break and if it goes bankrupt then I at least have many years where I do not have to pay tax on share gains and that is positive or... :) It is not going to go bankrupt for the next half year or so because now they have money well into mid-late 2027 Søren Bregenholt and the management of Alligator Bioscience AB should have allied with Saniona and Sprint Bioscience then they might have learned something about how to get lucrative deals closed in the biotech market without continuing to dilute shareholders. Just in the current year, it has fallen by 96.85 % .......... Good day out there and good wind Disclaimer: I own shares in Alligator Bioscience and this is not a recommendation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI may also be wrong in what it has found.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 105 | ||
| 3 328 | ||
| 470 | ||
| 341 | ||
| 81 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 350 801 | 8 350 801 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 350 801 | 8 350 801 | 0 | 0 |
2026 Q3 - tulosraportti
7 päivää sitten
‧32 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q4 - tulosraportti 11.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q3 - tulosraportti 22.10. | ||
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 5.5. | ||
2025 Q4 - tulosraportti 12.2. | ||
2025 Q3 - tulosraportti 23.10.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·1 päivä sittenIt will be interesting to see if I manage to lose 50.000 this year, the opportunities are there.Looking at the history of the board here, the same names keep appearing in several of the same companies. May seem like a network of familiar people. They also have no product success in any of their companies. Historically many share issues/reverse splits. These are people who know how to make money off the shareholders.
- ·1 päivä sittenWith a reverse split of 1:1000, the price at the current price will be 10kr. So if you previously had 625,000 shares at 0.01, after the split you will have 625 shares at 10 kr. The value will thus be the same. After this, there will definitely be a rights issue, where the issue price might be 5-7kr. What will then happen is that the price will plummet from 10kr to the issue price of maybe 5 or 7, or whatever the issue price turns out to be. So I think everyone can probably figure out that it is not very wise to buy shares in this one, or to hold them when the rights issue is announced....Hopefully Alligator will also bring in some money via TO15 and TO16.
- ·1 päivä sittenExciting to see how long Alligator can keep the death spiral going. There will probably be a new capital raise soon, where the guarantors get a hefty discount, so all ordinary shareholders can once again bear the brunt of a new massive dilution. Unfortunately, this method is quite popular for many small biotech companies (and often the only opportunity to get some cash in the box), but too little money is always raised to make a real difference for the company. The only ones who win from these small emissions are the guarantors, who exploit this trick to make money off naive small investors.The latest new share issue was subscribed to 17,1%. I don't think Alligator will bring in any more money via new share issues. Possibly Alligator will bring in some money via TO15 and TO16….
- ·23.10.So I have bought 625,000 for the risk portfolio - which is very small and plays with binary events. It can then sit until 2027-2028 and see if anything happens there.there is probably a risk of an emi going forward yes absolutely, unless they come up with something shortly
- ·22.10.Søren Bregenholt thanks for our patience :) During his time, the share has ONLY fallen by 99.999 % if we go back from when they started, the share has fallen by 99.9999 % meaning one 9 digit extra. It has been a joke to be an investor at Alligator Bioscience AB, they have made maximal dilution every single time but the funny thing is if they get through and succeed with HLX22 and Henlius gets it marketed and starts selling the medicine then Alligator Bioscience AB can have the potential to rise 10-100 times in a very short time. We will see if they go bankrupt or they are going up by 10-100 times. If they get their Mitazalimab project sold, it could potentially also rise many times, but as Søren just said, it is an agreement that will probably be made based on very little money upfront. I am staying in the share and then it must make or break and if it goes bankrupt then I at least have many years where I do not have to pay tax on share gains and that is positive or... :) It is not going to go bankrupt for the next half year or so because now they have money well into mid-late 2027 Søren Bregenholt and the management of Alligator Bioscience AB should have allied with Saniona and Sprint Bioscience then they might have learned something about how to get lucrative deals closed in the biotech market without continuing to dilute shareholders. Just in the current year, it has fallen by 96.85 % .......... Good day out there and good wind Disclaimer: I own shares in Alligator Bioscience and this is not a recommendation to either buy or sell shares in the company. Do your own analyses, I may be wrong in what I write and AI may also be wrong in what it has found.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä |
|---|---|---|
| 105 | ||
| 3 328 | ||
| 470 | ||
| 341 | ||
| 81 |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastoja ja ETF:iä jotka omistavat osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 350 801 | 8 350 801 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 8 350 801 | 8 350 801 | 0 | 0 |